Metabolic Imaging Predict Histopathologic Response to Preop ChemoXRT for Locally Advanced Rectal CA

Not Applicable

Terminated

• Conditions: Rectal Cancer

• Registration Number: NCT00394615
• Lead Sponsor: Stanford University

Brief Summary

In this research study of metabolic imaging in locally advanced rectal cancer, we hope to learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy. Ultimately we hope this information will in the future help us predict which patients will benefit from more or less aggressive initial therapy for their rectal cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-10
• Primary Completion: 2005-10
• Study Completion: 2005-10
• Study First Submitted: 2006-07-05
• Study First Submitted QC: 2006-10-31
• Study First Posted: 2006-11-01
• Status Verified: 2010-03
• Last Update Submitted: 2010-03-25
• Last Update Posted: 2010-03-29

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• You must be diagnosed with locally advanced rectal cancer and have chosen treatment with preoperative chemoradiotherapy followed by surgery, which is a standard treatment approach for this disease.

Exclusion Criteria

• You are ineligible for this study if you are pregnant or under the age of 18 years old.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
To learn whether new medical imaging technology can help predict the response of rectal cancer to preoperative chemotherapy and radiation therapy.

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States